期刊
JOURNAL OF MICROENCAPSULATION
卷 30, 期 2, 页码 181-188出版社
INFORMA HEALTHCARE
DOI: 10.3109/02652048.2012.714411
关键词
nanocapsules; nanocarrier; cancer therapy; docetaxel; polysaccharide; chitosan
资金
- Spanish Ministry of Science and Technology [SAF 2004-08319-CO2-01]
- Consolider Nanobiomed [CSD 2006-00012]
- Spanish Government [AP2005-1701]
- Xunta de Galicia (Spain)
This article describes the development of a freeze-dried formulation of chitosan (CS) nanocapsules containing docetaxel (DCX) and the evaluation of its efficacy in the NCI-H460 cancer cell line. More specifically, two prototypes of nanocapsules differing in their coating, CS alone or in combination with poloxamer 188 were developed using the solvent displacement technique. These prototypes (150nm and +45 mV) exhibited high encapsulation efficiencies of DCX (78%) and very similar release profiles. The nanocapsules made of solely CS could be freeze-dried and reconstituted without altering their particle size distribution. CS nanocapsules were tested for their ability to deliver intracellularly the anticancer drug DCX. The results showed that CS nanocapsules maintained the antiproliferative effect of the drug and that it was not affected by the freeze-drying process. Moreover, it was found that this cytostatic effect of DCX was related to its intracellular delivery in the cancer cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据